Last reviewed · How we verify

NCT03347656

Effects of Mobility Dose on Discharge Disposition in Critically Ill Stroke Patients

Completed Last updated 20 August 2024
What this trial tests

trial in Sarcopenia in 164 participants. Completed in 30 June 2021.

Timeline
12 October 2017
Primary endpoint
20 December 2019
30 June 2021

Quick facts

Lead sponsorBeth Israel Deaconess Medical Center
StatusCompleted
Study typeOBSERVATIONAL
Enrollment164
Start date12 October 2017
Primary completion20 December 2019
Estimated completion30 June 2021
Sites3 locations across United States, Germany

Conditions studied

Sponsor

Beth Israel Deaconess Medical Center

Who can join

18 and older, any sex, with Sarcopenia or Stroke, Acute. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary aim of the study is to assess the mobility dose in neurocritical care patients with ischemic stroke or intracranial hemorrhage and its effects on discharge disposition and patient outcomes. The investigators hypothesize that patients' mobilization dose in the intensive care unit (ICU) predicts discharge disposition, 90 day Barthel Index and other outcomes like muscle wasting (expressed as decrease in rectus femoris cross sectional area (RF-CSA) in the paretic and non-paretic limb measured by bedside ultrasound), and ICU length of stay (LOS).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Sarcopenia

Currently open trials in the same condition.

Other Beth Israel Deaconess Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03347656.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing